Drug & Device Advertising Year in Review: Lessons from 2025 FDA Enforcement & Key Developments

Join us for a review of key takeaways from the FDA’s 2025 drug and device advertising and promotion enforcement letters, along with a discussion of other noteworthy developments relevant to drug and medical device marketing.  

This roundtable will examine current FDA priorities and their implications, including trends in enforcement letters such as direct-to-consumer advertising and promotion, DTC television ads, CFL efficacy claims, and policy priorities. We will also address related developments, including the status of “Adequate Provision,” the role of social media and influencers, and recent FTC updates, as well as predictions for what may be expected in 2026. 

For questions or for information about reigistration, contact Sydney Forte.